Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience

被引：0

作者：

Yoshihide Ueda

Tsuyoshi Kobayashi

Toru Ikegami

Satoshi Miuma

Shugo Mizuno

Nobuhisa Akamatsu

Akinobu Takaki

Masatoshi Ishigami

Mitsuhisa Takatsuki

Yasuhiko Sugawara

Yoshihiko Maehara

Shinji Uemoto

Hiroshi Seno

机构：

[1] Kyoto University,Department of Gastroenterology and Hepatology, Graduate School of Medicine

[2] Hiroshima University,Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences

[3] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences

[4] Nagasaki University Graduate School of Biomedical Sciences,Department of Gastroenterology and Hepatology

[5] Mie University School of Medicine,Department of Hepatobiliary Pancreatic and Transplant Surgery

[6] University of Tokyo,Division of Artificial Organ and Transplantation, Department of Surgery

[7] Okayama University Graduate School of Medicine,Department of Gastroenterology and Hepatology

[8] Dentistry and Pharmaceutical Sciences,Department of Gastroenterology and Hepatology

[9] Nagoya University Graduate School of Medicine,Department of Surgery

[10] Nagasaki University Graduate School of Biomedical Sciences,Department of Transplantation and Pediatric Surgery, Postgraduate School of Medical Science

[11] Kumamoto University,Department of Surgery, Graduate School of Medicine

[12] Kyoto University,undefined

来源：

Journal of Gastroenterology | 2019年 / 54卷

关键词：

Hepatitis C; Liver transplantation; Glecaprevir; Pibrentasvir;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：660 / 666

页数：6

共 53 条

[1]

Berenguer M(2018)Registry by the Japanese Liver Transplantation Society Jpn J Transplant. 53 109-123

[2]

Ferrell L(2000)HCV-related fibrosis progression following liver transplantation: increase in recent years J Hepatol 32 673-684

[3]

Watson J(2012)Liver transplantation in the setting of chronic HCV Best Pract Res Clin Gastroenterol 26 531-548

[4]

Terrault N(2016)Interferon-free therapy for hepatitis C in liver transplant recipients Transplantation 100 54-60

[5]

Ueda Y(2017)ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients J Hepatol 67 585-602

[6]

Uemoto S(2017)Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience J Gastroenterol 52 986-991

[7]

Belli LS(2018)Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis c virus infection Hepatology 68 1298-1307

[8]

Duvoux C(2018)Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis J Gastroenterol 53 557-565

[9]

Berenguer M(2018)Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection Hepatology 67 505-513

[10]

Ueda Y(1997)New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a J Clin Microbiol 35 201-207

← 1 2 3 4 5 6 →